Ibuprofen/Famotidine

布洛芬/法莫替丁

Report date: 2024/02/28 20:04:05

Base Information

Drug NameIbuprofen/Famotidine
Drug Alias Name法莫替丁/布洛芬Famotidine/Ibuprofen法莫替丁+布洛芬DuexisHZT-501
ClassificationSmall molecules
Mechanisms of ActionHistamine H2 receptor antagonistsCyclooxygenases inhibitors
TargetsHistamine H2 receptorCyclooxygenases
Therapy Area/IndicationsLow Back PainUlcerComplex Regional Pain Syndromes +[6] 
Global Approved IndicationsUlcerOsteoarthritisArthritis, Rheumatoid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/04/23
Country/TerritoryUnited States
CombinationsYes IbuprofenFamotidine
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesHorizon Therapeutics PLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHorizon Therapeutics PLCAmgen Inc
Active IndicationsN/A
Inactive IndicationsLow Back PainUlcerComplex Regional Pain Syndromes +[6] 

Other Information

ATC CodeM01AE51
Related LinksN/A